Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
Seer (Nasdaq: SEER), a company specializing in proteomic insights, has scheduled its Q2 2025 financial results announcement for August 6, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER), a company specializing in proteomic insights, has scheduled its Q2 2025 financial results announcement for August 6, 2025. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day.
Investors can access the live webcast through the Investor section at investor.seer.bio, where an archived replay will also be available after the event.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Consort Partners
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.